At week 30, Suliqua® significantly reduced HbA1c by 1.6% in a pivotal trial1-2
Suliqua® reduced HbA1c by 2.9% in a post hoc supgroup analysis of patients with HbA1c of >9%3
Suliqua® is a favourable alternative to premixed insulins when intensifying from metformin + basal insulin + OADs4
- SULIQUA® SmPC as of May 2021.
- Rosenstock J, Aronson R, Grunberger G, et al. Diabetes Care. 2016;39:2026-2035.
- Davies MJ, Russell-Jones D, Barber TM, et al. Diabetes Obes Metab. 2019:21:1967-1972.
- Rosentock J, Emral R, Sauque-Reyna L, et al. Diabetes Care. 2021:dc210393;D0I: 10.2337/dc-21-0393.
Download guides about dosing and titration of Suliqua and more information on risk minimisation.
Watch and listen to your peers discussing rapid-acting biosimilars and their best practices while using them.
Post GLP-1 Therapy
Nurse Grace Vanterpool gives an overview of how to use Suliqua in patients post GLP-1 therapy.
Post Insulin Therapy
Nurse Grace Vanterpool gives an overview of how to use Suliqua in patients requiring intensification of a basal insulin regimen.
Post Oral Therapy
Nurse Grace Vanterpool gives an overview of how to use Suliqua in insulin naïve patients.
Using Suliqua in Clinical Practice
Dr Amar Ali gives a brief overview of Suliqua®, including how to choose the appropriate Suliqua pen when prescribing in clinical practice and illustrates his experience with a case study.
Date of Preparation: June 2022